Archive for the ‘Healthcare’ Category
A recent advertisement for Pfizer’s new hormonal therapy for postmenopausal patients, Estring, caught the attention of the FDA’s Office of Prescription Drug Promotion in a bad way. In this direct-to-consumer promotion, spokespeople for Estring, depicted in the ad as doctor and patient, discuss the new treatment, with the patient proclaiming that she had suffered no side effects. Unfortunately for Pfizer, any plausible side effects must be brought to the attention of consumers, even if this particular case showed none. This resulted in a chastising letter for Pfizer.
Though Pfizer might not agree, this story…
Recently sworn-in commissioner of the Food and Drug Administration (FDA) Dr. Scott Gottlieb has affirmed his stance on the vaccination debate in many instances, but a recent Twitter post is sure to make his intentions on the matter perfectly clear. Unlike the man who appointed him to his position, President Donald Trump, toes the line of anti-vaccine and pro-vaccine, Gottlieb is embracing his new status to spread scientific data and other newsworthy tidbits on the matter.
In a message to his followers, Dr. Gottlieb shared an infographic the country before and…
ExL Events would like to congratulate our speaker alumnus Dr. Scott Gottlieb for the recent United States Senate confirmation, naming him the new Food and Drug Administration commissioner. Dr. Gottlieb was the keynote speaker at ExL’s 2nd Trial Design Innovation Conference and was also a featured speaker at our Private Fee-for-Service event.
President Donald Trump nominated Gottlieb earlier this year, for his previous service as deputy commissioner for the FDA, as well as his experience in the pharmaceutical and health care industries. As the FDA’s newly appointed commissioner, Gottlieb will…
From The Blog
- Commercial Strategy
- Content Marketing
- Data Management
- Digital Marketing
- Drug Safety
- Emerging Markets
- ExL Events News
- Medical Devices
- Medical Education
- Meeting Planning
- Patient Engagement
- Public/Government Relations
- Regulatory Affairs